CONTROVERSES ET ACTUALITÉS EN CHIRURGIE VASCULAIRE CONTROVERSIES & UPDATES IN VASCULAR SURGERY JANUARY 19-21 2017

MARRIOTT RIVE GAUCHE & CONFERENCE CENTER
PARIS, FRANCE

Natural history of autologous arteriovenous fistulae and consequences for planning of dialysis access

Teun Wilmink, Lee Hollingworth, Sarah
Powers, Clive Allen, Indranil Dasgupta
Dept of Vascular Surgery and Renal Medicine.
Heart of England NHS Foundation Trust,
Birmingham







## **Disclosure** Speaker name: Teun Wilmink I have the following potential conflicts of interest to report: Consulting Employment in industry Shareholder in a healthcare company Owner of a healthcare company Other(s) I do not have any potential conflict of interest



### Objective



To accurately estimate PF rates, maturation-times, and the longterm survival of common AVF to inform decision-making in access planning





- Study from 1 Dec 2002 31 Dec 2011
- Follow up till 1 Dec 2014
- AVF is deemed mature after 6 consecutive dialysis sessions on AVF with 2 needles
- PF is failure to achieve maturation.
- Maturation time is to 6<sup>th</sup> needling date
- Survival is defined as date when AVF is abandoned for a new form of access

Wilmink, EJVES: 2016;51(1):134-40.

## Primary Failure



Type AVF	Dialysis use	PF	Total
RCAVF	491 (74%)	173 (26%)	664 (57%)
BCAVF	311 (83%)	66 (17%)	377 (32%)
BBAVF	90 (74%)	32 (26%)	122 (10%)
Total	892 (77%)	271 (23%)	1163 (100%)

 $\chi 2 = 10.5 P = 0.005$ 



### Predictors for PF



Factor	Yes	No	P value
female	28%	20%	0.003
diabetes	25%	22%	0.43
On dialysis	24%	23%	0.52
Previous AVF	23%	23%	0.98
Access surgeon	23%	24%	0.70
Mean age (95% CI)	66 (15)	66 (16)	0.53

### Independent predictors of PF



Variable	OR	95% CI	P value
Female sex	1.61	1.21 – 2.14	0.001
BCAVF	0.59	0.42 - 0.83	0.003
vascular CKD	1.93	1.24 – 3.02	0.004

 Previous AVF, diabetes, surgeon, dialysis state did not predict PF







PARIS, FRANCE

percentile	1 <sup>st</sup> needling date	Maturation date
10	3.5	4.9
25	5.3	7.3
median	7.9	10
75	12.7	16
90 www.cacvs.org	26.3	29.4

www.cacvs.org



#### Maturation times



Type AVF	25%	Median	<b>75%</b>
RCAVF	7	10	17
BCAVF	7	9	13
BBAVF	9	13	19

P = 0.002






## Maturation simplified

- Half of the fistulae are mature after 10 weeks
- Three quarters are mature after
   16 weeks
- 90% of fistulae are mature after
   29 weeks






## Survival by type AVF








## Survival by type AVF





## Survival by dialysis state JANUARY








# Multivariate survival analysisary 19-21 2017

Variable	HR	95% CI	Р
Type AVF	1.36	1.13 – 1.62	0.001
On dialysis	1.62	1.20 - 2.18	0.001
Six from start	0.67	0.51 - 0.88	0.004
diabetes	1.44	1.12 - 1.86	0.004
age	1.00	0.99 - 1.01	0.136
sex	1.09	0.84 - 1.40	0.514



### Survival by successful needling










## Successful needling



## Weeks needed?



	median	p75
Maturation time	10	16
Wait for assessment	3	6
Wait for operation	4	7
Total	17	29

## Decline eGFR in weeks




Percentile	15 to 10	20 to 10
p10	0.3	1.3
p25	2.4	15
median	17	50
p75 //	48	112
p90	91	193

#### CONTROVERSES ET ACTUALITES EN CHIRURGIE VASCULAIRE CONTROVERSIES & UPDATES IN VASCULAR SURGERY




## Decline eGFR by cause





## Estimation expected dialysis date





### Lessons learnt



- RCAVF's have best survival
- Age should not influence choice of AVF
- AVF survival is much better in predialysis patients
- 75% of AVF are needled in 16 weeks
- Decline in eGFR is highly individual
- We need individual prediction of estimated dialysis date